US-based genomics start-up Variant Bio has announced a multi-year partnership deal with Novo Nordisk (NYSE: NVO) to jointly discover novel targets for the treatment of metabolic diseases. The collaboration is designed to identify and validate multiple innovative targets with strong human genetic evidence, paving the way for human-centric drug discovery programs.
Role of Variant Bio’s Platform
Variant Bio will utilize its innovative VB-Inference analysis platform to identify novel targets with robust genetic evidence and clear therapeutic hypotheses. This platform has already enabled several new R&D programs within Variant Bio’s internal pipeline. It maps the molecular mechanisms of disease by integrating whole genomes with deep phenotyping and rich multi-omic data, leveraging statistical genetics and machine learning.
Significance of the Partnership
This partnership underscores the commitment of both Variant Bio and Novo Nordisk to advancing the understanding and treatment of metabolic diseases. By combining Variant Bio’s advanced genomics capabilities with Novo Nordisk’s expertise in drug development, the collaboration aims to accelerate the discovery of innovative therapies that could significantly improve patient outcomes.-Fineline Info & Tech
